Combined modality treatment has been the standard option for the treatment of early stage Hodgkin lymphoma for several decades. Because of the high success rate and the risk of late toxicities, recent clinical trials have focused on reducing the treatment burden. Field and dose of radiotherapy, and number of cycles of chemotherapy have been successfully reduced, particularly for favourable early stage patients. However, the impact of these treatment reductions on the rate of secondary malignancies remains still unclear. Positron emission tomography-computed tomography (PET-CT) scanning has emerged as a very important tool for disease staging and end of treatment assessment. Interestingly, a PET performed after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) has been correlated with final outcome and was recently evaluated in a randomized clinical trial to evaluate individualized therapy based on PET response after 2 or 3 cycles of ABVD. These trials aimed to identify good prognosis (early PET-negative) patients who could be spared radiotherapy, but also patients with a bad prognosis (early PET-positive) who need more intensive treatment. More recently, new drugs, such as brentuximab vedotin and checkpoint inhibitors, have shown efficacy in relapsed/refractory patients and are currently under evaluation in early stage patients.
The treatment of early stage Hodgkin lymphoma (HL) is one of the great successes in modern oncology with the vast majority of patients cured of their disease. Given the success of initial therapy, the approach towards management has therefore increasingly focused on the quality of long-term survival, where a high rate of treatment-induced mortality and morbidity has been observed . This has led to the observation in long-term follow-up that more patients are dying from the consequences of treatment than from HL (Aleman et al, 2003) . These late effects most often occur decades after treatment and are mainly well documented in patients who received higher dose extended radiation fields, which have long since been abandoned in the modern era of lower dose involved site radiotherapy (RT) (Maraldo et al, 2014) . Therefore, the most recent trials have evaluated response-adapted therapies with the goal to reduce the late side effects while maintaining the curative potential of the treatments. More recently, new drugs, such as brentuximab vedotin and checkpoint inhibitors, became available and could potentially also help to reach this goal. This paper reviews the management of classical HL and does not discuss the rare sub-entity of nodular lymphocyte predominant HL.
Prognostic factors
The initial staging of HL is performed by positron emission tomography-computed tomography (PET-CT) scan (PET), as recommended by the Lugano classification (Cheson et al, 2014) . Interestingly, a bone marrow biopsy (BMB) is no longer required when a PET is performed for initial staging (El-Galaly et al, 2012; Eichenauer et al, 2018) . In the study reported by El-Galaly et al (2012) , 18% of patients had focal skeletal lesions on PET-CT, but only 6% had positive BMB. None of the patients would have been allocated to another treatment based on BMB results. Patients with early-stage HL rarely show disease involvement in the absence of a suggestive PET finding, confirming that, if a PET-CT is performed, a bone marrow aspirate/biopsy is no longer required for the routine evaluation of patients with HL.
Once a patient is diagnosed with an early stage HL, clinical risk factors are commonly used to separate these patients in two categories: favourable versus unfavourable/intermediate. These categories were established decades ago and are based on B symptoms, erythrocyte sedimentation rate (ESR), bulky mediastinum (defined on chest X-ray), number of involved nodal areas, age and extra-nodal areas (Table I) . Unfortunately, there are some differences between the classifications used by cooperative groups, which sometimes makes comparison of different studies very challenging.
Long term side effects
The most severe late effect of therapy for HL is second cancer. In a recent large study , with a median follow-up of 19Á1 years, the standardized incidence ratio (SIR) was 4Á6 [95% confidence interval (CI), 4Á3-4Á9] in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3Á9; 95% CI, 2Á8-5Á4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48Á5% (95% CI, 45Á4-51Á5). Unfortunately, the cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988 or 1989-2000) (P = 0Á71 for heterogeneity), suggesting that the efforts made to reduce the burden of treatment did not translate into a reduction in second cancers. However, the impact of treatment modifications in the last 20 years is currently not well known. Also, as the risk is better known, it might be suggested that well-conducted cancer screening programmes could also reduce the severity of late malignancies. However, a recent study found that many women are not getting the proper dual screening for breast cancer despite their increased risk, with only 36Á6% of the study sample receiving dual screening (Baxstrom et al, 2018) . Proper screening allows for detection of secondary breast cancer at earlier stages, where treatment can be localised therapy, but this study raised the issue of compliance of this population to cancer screening programmes. Finally, cancer screening is not yet possible for thyroid, lung and soft tissue cancers.
Cardio-vascular and valvular diseases are another important late effect that can occur in patients receiving mediastinal RT (Cutter et al, 2015; Hahn et al, 2017) . The decrease in the doses and volume of RT used led to a reduction of these complications. Nevertheless, RT may still result in substantial incidental cardiac exposure if the disease affects the mediastinum.
Non PET-adapted treatment strategies
Extended-field (EF) RT was the first established treatment to cure a large proportion of early-stage HL. However, two large randomized trials performed by the German Hodgkin Study Group (GHSG) and European Organization for Research and Treatment of Cancer/Lymphoma Study Association (EORTC/LYSA) demonstrated a better disease control with the combination of chemotherapy and RT. In the H8 study, EF-RT was compared to 3 cycles of nitrogen mustard, vincristine, procarbazine and prednisone alternating with adriamycin, bleomycin and vinblastine (MOPP-ABV) and involved-field (IF) RT and showed a significantly higher progression-free survival (PFS) (74% vs. 98%, P = 0Á001) (Ferme et al, 2007) . Similar results were shown in the HD7 trial of the GHSG (Engert et al, 2007) , defining combined modality treatment (CMT) as a new standard of care.
Favourable early stage
To further reduce long-term toxicities, a reduction of the dose of RT was evaluated for early favourable HL patients. The HD10 GHSG study is a two by two design trial with the aim to compare both 4 versus 2 cycles of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) and 30 Gy vs. 20 Gy of IF-RT . There was no difference between 2 and 4 cycles of ABVD with respect to freedom from treatment failure (P = 0Á39) or overall survival (OS) (P = 0Á61). At 5 years, the rates of freedom from treatment failure were 93Á0% (95% CI, 90Á5-94Á8) with the 4-cycle ABVD regimen and 91Á1% (95% CI, 88Á3-93Á2) with the 2-cycle regimen. When the effects of 20 Gy and 30 Gy doses of RT were compared, there were also no significant differences in freedom from treatment failure (P = 1Á00) or OS (P = 0Á61). Adverse events and acute toxic effects of treatment were most common in the patients who received four cycles of ABVD and 30 Gy RT. (Ferme et al, 2007) GHSG (Engert et al, 2007) Canada (Meyer et al, 2012) Risk The similar efficacy of the 20 Gy regimen was recently confirmed in the EORTC-LYSA H9-F (Thomas et al, 2018) . All patients received 6 cycles of epirubicin, bleomycin, vinblastine and prednisone (EBVP). Those who obtained a complete response or unconfirmed complete response were randomized to receive either 36 Gy IF-RT, 20 Gy IF-RT or no further RT. Results in the 20 Gy arm [5-year relapse-free survival (RFS), 84Á2%] were not inferior to those in the 36 Gy arm (5-year RFS, 88Á6%) (Difference: 4Á4%; 90% CI, À1Á2 to 9Á9%).
A reduction in disease control was observed for the no RT arm (Thomas et al, 2018) . After the inclusion of 130 patients in the no RT arm, this arm was prematurely stopped because of a 20% rate of unacceptable events: toxicity, treatment modification, early relapse or death. The study could not demonstrate noninferiority of the no RT arm, its primary endpoint, (5-year RFS estimate, 69Á8%) compared with the 36-Gy arm (86Á3%) with a difference of 16Á5% (90% CI, 8Á0-25Á0%) between the 2 arms, because the upper bound of the 90% CI exceeded the prespecified noninferiority margin (10%); the hazard ratio (HR) estimate was 2Á55 (95% CI, 1Á44-4Á53; P < 0.001). However, no difference in OS was observed between the 3 different arms.
Similarly, another study evaluated the omission of RT in unselected early favourable patients. Meyer et al (2012) randomized 405 patients with previously untreated stage IA or IIA non-bulky HL to ABVD alone or to a treatment with subtotal nodal RT, with or without ABVD. The median length of follow-up was 11Á3 years. At 12 years, the rate of OS was 94% among those receiving ABVD alone, as compared with 87% among those receiving RT (HR for death with ABVD alone, 0Á50; 95% CI, 0Á25-0Á99; P = 0Á04); the rates of freedom from disease progression were 87% and 92% in the two groups, respectively (HR for disease progression, 1Á91; 95% CI, 0Á99-3Á69; P = 0Á05). This study showed that omission of RT in unselected patients was associated with an inferior disease control. However, survival was better in the no-RT arm; whereas among the 24 deaths in the RT arm, 4 were related to HL or early toxic effects of treatment and 20 were related to another cause. Finally, at the time the study was published (around 20 years after initial recruitment), the RT used (Subtotal nodal RT) had become outdated and replaced by IF-RT as standard practice.
In the HD13 study of the GHSG, reduction of chemotherapy was evaluated by omission of bleomycin and/or dacarbazine because of the toxicity of these drugs (Behringer et al, 2015) . Both the assignment to the AV and ABV arms were stopped early due to a high event rate (relapse or death). Assignment to ABVD and AVD could continue until the end of the trial. Non-inferiority of AVD compared with ABVD could also not be detected (5-year difference: À3Á9%, 95% CI, À7Á7 to À0Á1; HR 1Á50, 95% CI, 1Á00 to 2Á26). According to this study, the standard of care for patients with early-stage favourable HL should remain ABVD followed by IF-RT.
Unfavourable early stage
The use of large-field RT was abandoned after both the GHSG HD8 (Engert et al, 2003) and the EORTC/LYSA H8U (Ferme et al, 2007) trials. HD8 demonstrated long-term noninferiority of IF-RT compared with EF-RT. With regard to treatment-associated long-term toxicity, a non-significant trend toward less secondary neoplasia with IF-RT was observed in the recent follow-up analysis (15-year cumulative, 14% vs. 17%; P = 0Á3) (Sasse et al, 2017) . This trend is more pronounced when examining only the incidence of acute myeloid leukaemia or myelodysplastic syndromes (2Á4% vs. 0Á8%; P = 0Á1), but not in non-Hodgkin lymphoma (2Á6% vs. 2Á9%; P = 1Á0). In solid second neoplasia, the trend became more pronounced with longer follow-up but did not reach statistical significance (12% vs. 10Á4%; P = 0Á7). Because of the long latency of solid second neoplasia, prolonged follow-up is crucial to finally assess the risk of secondary neoplasia with more limited RT fields.
Among the 766 patients who had a confirmed or unconfirmed complete remission after RT in H8U, 42 (5%) relapsed: 15 of 253 patients (6%) in the group receiving six cycles of MOPP-ABV plus IF-RT, 14 of 259 patients (5%) in the group receiving four cycles of MOPP-ABV plus IF-RT, and 13 of 254 patients (5%) in the group receiving MOPP-ABV plus subtotal nodal RT (Ferme et al, 2007) . There were no significant differences in the 5-year event-free survival (EFS) estimates among the three groups.
Therefore, after these two trials, 4 cycles of ABVD and 30 Gy IF-RT was considered as a standard of care.
The GHSG HD11 study was a two by two design study that aimed to compare two different chemotherapy regimens in unfavourable early stage HL: 4 cycles ABVD vs. 4 cycles BEACOPP baseline (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) ; and 30 Gy IF-RT vs. 20 Gy . No improvement was demonstrated using 4-cycle BEACOPP baseline versus ABVD. Concerning RT, the 20 Gy arm was inferior to 30 Gy when ABVD was used but when BEACOPP was used this difference disappeared and 20 Gy was equivalent to 30 Gy.
Similarly, the EORTC/LYSA H9U study compared 6 cycles ABVD and 30 Gy IF-RT (standard arm) vs. 4 cycles ABVD and 30 Gy IF-RT and 4 cycles BEACOPP baseline and 30 Gy IF-RT . Results in the 4-cycle ABVD and IF-RT (5-year EFS, 85Á9%) and the 4-cycle BEACOPP baseline and IF-RT (5-year EFS, 88Á8%) were not inferior to 6 cycles ABVD and IF-RT (5-year EFS, 89Á9%): difference of 4Á0% (90% CI, À0Á7 to 8Á8%) and 1Á1% (90% CI, À3Á5 to 5Á6%) respectively. The 5-year OS estimates were 94%, 93% and 93%, respectively. Because 4 cycles of BEACOPP baseline were more toxic but equally efficient to 4 cycles of ABVD, it was not considered as a new standard.
As there is a potential to improve the disease control obtained with 4 cycles of ABVD and RT, the GHSG HD14 trial compared 4 cycles ABVD and 30 Gy IF-RT vs. 2 cycles of escalated BEACOPP (BEACOPP esc ) plus 2 cycles ABVD and 30 Gy IF-RT. It resulted in a significant PFS advantage for «2 + 2» compared with 4cycles ABVD, with a 5-year PFS of 6Á2% (95Á4% vs. 89Á1%; HR, 0Á45; 95% CI, 0Á3-0Á69) (von Tresckow et al, 2012) . This «2 + 2» approach is associated with more acute, predominantly haematological, toxicity, but no difference in long-term toxicity or OS has been documented so far. A longer follow-up is needed to assess potential long-term benefits and risks with upfront intensive therapy in patients with early-stage unfavourable disease.
PET-adapted treatment strategies Gallamini et al (2007) consecutively enrolled 260 newly diagnosed HL to evaluate the prognostic role of an interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (iPET). Most of the patients were advanced HL and the study showed that iPET overshadows the prognostic value of the International Prognostic Score and emerges as the single most important tool for planning risk-adapted treatment in advanced HL (Gallamini et al, 2007) . A similar evaluation conducted in 257 stage I to IIA patients treated with chemotherapy plus RT, led to a similar conclusion and showed that iPET was a strong prognostic factor for both PFS and OS (Simontacchi et al, 2015) .
Consequently, several trials were launched in order to evaluate early treatment adaptation according to iPET results after 2 or 3 cycles of ABVD.
Favourable early stage
In the UK RAPID (Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/ IIA Hodgkin's Disease) trial, 602 patients with newly diagnosed stage IA or stage IIA HL underwent iPET after receiving 3 cycles of ABVD (Radford et al, 2015) . RAPID included both favourable (2/3) and unfavourable (1/3) early stage HL in the same trial. Patients with negative iPET findings [Deauville score (DS), 1 or 2] were randomly assigned to receive IF-RT or no further treatment; patients with positive iPET findings (DS, 3-5) received a fourth cycle of ABVD and RT. Approximately two-thirds of patients enrolled had a favourable risk profile according to GHSG or EORTC/LYSA risk classification (personal communication, J Radford, Institute of Cancer Sciences, University of Manchester, Manchester, UK). The 3-year PFS rate was 94Á6% (95% CI, 91Á5-97Á7) in the RT group and 90Á8% (95% CI, 86Á9-94Á8) in the group that received no further therapy, with an absolute risk difference of À3Á8 percentage points (95% CI, À8Á8 to 1Á3). As the upper CI limit exceeded the predefined noninferiority margin of 7%, the study did not show noninferiority of the strategy of no further treatment. Nevertheless, patients in this study with early-stage HL and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation RT. The impact on OS and late effects need additional follow-up.
The EORTC/LYSA/Fondazione Italiani di Limfomi (FIL) H10 study also evaluated an early treatment adaptation according to iPET (Andr e et al, 2017). In the favourable group (patients without any of the following: age ≥50 years, more than three nodal areas, mediastinal-thoracic ratio ≥0Á35, no B symptoms and ESR ≥ 50 or B symptoms and ESR ≥ 30) received 2 cycles ABVD followed by an iPET. In the standard arm iPET-negative patients [according to International Harmonization Project criteria (Juweid et al, 2007)] were randomized between 1 additional cycle of ABVD and 30 Gy involved-node (IN) RT versus 2 cycles of ABVD. Among the 465 iPET-negative patients, after a median follow-up of 5Á0 years, a total of 33 events for PFS occurred: two patients experienced relapse in the ABVD + IN-RT arm versus 30 patients who experienced relapse and one patient died from a cause not related to lymphoma in the ABVDonly arm. Intention to treat (ITT) 5-year PFS rates were 99Á0% (95% CI, 95Á9-99Á7) and 87Á1% (95% CI, 82Á1-90Á8) in the ABVD + IN-RT and ABVD only arms, respectively, with HR, 15Á8 (95% CI, 3Á8-66Á1) in favour of ABVD + IN-RT. Noninferiority could not be demonstrated because the upper bound of the 95% CI for the estimated HR (66Á07) exceeded the pre-specified noninferiority margin (3Á2).
In the Cancer and Leukemia Group B (CALGB) 50 604 phase 2 trial, patients with non-bulky stage I/II disease with a negative iPET (135 of 149 patients, DS, 1-3) after 2 cycles of ABVD were treated with an additional 2 cycles of ABVD without consolidative RT, whereas patients with a positive iPET (14 of 149 patients) received 2 cycles of BEACOPP esc and 30 Gy IF-RT. The estimated 3-year PFS rates were 91% and 66%, respectively, for the iPET-negative and PET-positive cohorts (P = 0Á011), HR 3Á84 (95% CI, 1Á50-9Á84) (Straus et al, 2018) . These data support that four cycles of ABVD results in durable remissions for the majority of patients with early stage non-bulky HL and negative iPET.
In summary, in the context of favourable patients, RAPID (Radford et al, 2015) and EORTC/LYSA/FIL H10 (Andr e et al, 2017), although showing several differences in their respective design (Table II) , and on the basis of the preset assumptions, showed that CMT resulted in a better immediate disease control and noninferiority of the no RT arm could not be demonstrated in iPET negative patients.
One additional study (GHSG HD16, NCT 0073632) has also evaluated this strategy in the context of early favorable HL and compares 2 cycles ABVD and IF-RT versus 2 cycles ABVD. Recruitment is completed but results are pending.
Unfavorable early stage
About one third of the patients included in RAPID trial (Radford et al, 2015) meet the criteria for unfavourable patients. The EORTC/LYSA/FIL H10 trial is the only published study to evaluate an iPET approach in the specific Review group of unfavourable HL (Andr e et al, 2017) . Unfavourable patients were defined as: age ≥50 years, large mediastinal mass [M/T ratio ≥0Á35, elevated ESR (with B symptoms, ≥30 mm/h; without B symptoms, ≥50 mm/h), >3 nodal areas]. Patients with a negative iPET were randomized between 4 cycles ABVD and IN-RT (n = 292) versus 6 cycles ABVD (n = 302). After a median follow-up of 5Á1 years, a total of 54 events for PFS occurred: 16 patients experienced relapse and six died from causes not related to HL in the ABVD + IN-RT arm, whereas 30 patients experienced relapse and two died from causes not related to HL in the ABVDonly arm. ITT 5-year PFS rates were 92Á1% (95% CI, 88Á0-94Á8) and 89Á6% (95% CI, 85Á5-92Á6) in the ABVD + IN-RT and ABVD only arms, respectively, with HR, 1Á45 (95% CI, 0Á8-2Á5) in favour of ABVD + IN-RT. Noninferiority could not be demonstrated because the upper bound of the 95% CI for the estimated HR (2Á50) exceeded the prespecified noninferiority margin (2Á10). However, the difference for the 5-years PFS is only 2Á5% (95% CI: À6Á6 to 0Á5%), within the range of the 10% prespecified noninferiority margin. Therefore, in this group of unfavourable patients, the benefit of CMT seems to be less clinically relevant than in the favourable group. Sparing selected unfavourable patients from large/mediastinal RT fields might be appropriate in the context of young age or pre-existing cardiovascular and pulmonary diseases.
The GHSG HD17 study (NCT 01356680), evaluating iPET-adapted treatment in unfavourable patients, has completed recruitment but results are pending. This trial compares 2 cycles BEACOPP esc + 2 cycles ABVD, with or without RT, in iPET-negative patients.
Management of iPET positive patients
In the RAPID (Radford et al, 2015) , GHSG HD16 and HD17, patients with a positive iPET received the standard arm of treatment. So far, only the data from RAPID have been published (Radford et al, 2015) . Among the 571 patients enrolled in the study and having an iPET after 3 ABVD, 145 were iPET-positive (DS 3-5) and 127 of the 145 patients (87Á6%) in the group with positive PET findings were alive without disease progression. There has been 18 events in this group; 10 events of disease progression (6Á9%), 5 deaths with disease progression (3Á4%), and 3 deaths without disease progression (2Á1%). A total of 8 of the 14 patients (57Á1%) in this group who received second-line treatment underwent transplantation.
The EORTC/LYSA/FIL H10 study grouped both favourable and unfavourable iPET-positive patients together, because of their presumed shared poor prognosis, in a randomized trial comparing 3-4 cycles ABVD and RT versus 2 cycles ABVD + 2 cycles BEACOPP esc + IN-RT (Andr e et al (2017) . In the overall iPET-positive group (n = 361), after a median follow-up of 4Á5 years, a total of 57 events for PFS occurred: 41 (36 relapses and 5 deaths not related to HL) in the ABVD + IN-RT arm and 16 (13 relapses and 3 deaths not related to HL) in the BEACOPP esc + IN-RT arm. ITT 5-year PFS rates were 77Á4% (95% CI, 70Á4-82Á9) and 90Á6% (95% CI, 84Á7-94Á3) in the ABVD + IN-RT and BEACOPP esc + IN-RT arms, respectively, with HR, 0Á42 (95% CI, 0Á23-0Á74; P = 0Á002) in favour of BEACOPP esc + IN-RT. The 5-year OS rates were 89Á3% vs. 96Á0% for ABVD + IN-RT and BEACOPP esc + IN-RT, respectively, with HR, 0Á45 (95% CI, 0Á19-1Á07; P = 0Á062 (Fig 1) .
European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and personal recommendations
The recently published ESMO guidelines (Eichenauer et al, 2018) recommend that patients with early stage favourable disease should receive either 2 cycles ABVD and 20 Gy involved site (IS) RT or 2 cycles ABVD and an iPET; if iPET-negative, patients should be treated with 1 cycle ABVD and 20 Gy IS-RT; iPET-positive patients should receive 2 cycles BEACOPP esc and 30 Gy IS-RT. Intermediate/unfavourable stage patients should be treated with 4 cycles For intermediate or unfavourable disease and bulky mediastinum, several options are discussed, including the GHSG HD14 and EORTC/LYSA/FIL H10 approaches but also Stanford V (Hoppe et al, 2017) .
Although several approaches are possible, we do recommend an iPET-guided strategy. For early stage favourable patients, an iPET is performed after 2 cycles ABVD. 
Conclusions and future strategies
The reduction of chemotherapy dose and size of RT, but also more recently, PET-adapted strategies have reduced the burden of treatment in early stage HL. Unfortunately, there is currently no evidence that this could reduce long-term toxicities. Recently, three new drugs (brentuximab vedotin, nivolumab and pembrolizumab) have shown very interesting results in relapsing patients (Younes et al, 2012 (Younes et al, , 2016 Chen et al, 2017) . These drugs are now also actively evaluated in first-line for early stage HL, either alone (i.e. in elderly patients) or in combination with AVD (NCT 02292979, NCT 02567851). Bleomycin is omitted in this situation because of increased lung toxicity. Phase II data show very promising data, but only randomized phase III trials can change the standard of care in this highly curable group of patients. Finally, circulating cell-free DNA could emerge as a very interesting tool to refine response evaluation and better define cure (Spina et al, 2018) .
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